BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Melki I, Devilliers H, Gitiaux C, Bondet V, Belot A, Bodemer C, Quartier P, Crow YJ, Duffy D, Rodero MP, Bader Meunier B. Circulating Interferon‐α Measured With a Highly Sensitive Assay as a Biomarker for Juvenile Inflammatory Myositis Activity: Comment on the Article by Mathian et al. Arthritis Rheumatol 2019;72:195-7. [DOI: 10.1002/art.41096] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Graf M, von Stuckrad SL, Uruha A, Klotsche J, Zorn-Pauly L, Unterwalder N, Buttgereit T, Krusche M, Meisel C, Burmester GR, Hiepe F, Biesen R, Kallinich T, Stenzel W, Schneider U, Rose T. SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies. RMD Open 2022;8:e001934. [PMID: 35177553 DOI: 10.1136/rmdopen-2021-001934] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Schänzer A, Rager L, Dahlhaus I, Dittmayer C, Preusse C, Della Marina A, Goebel HH, Hahn A, Stenzel W. Morphological Characteristics of Idiopathic Inflammatory Myopathies in Juvenile Patients. Cells 2021;11:109. [PMID: 35011672 DOI: 10.3390/cells11010109] [Reference Citation Analysis]
3 Stenzel W, Goebel HH, Bader-Meunier B, Gitiaux C. Inflammatory myopathies in childhood. Neuromuscul Disord 2021;31:1051-61. [PMID: 34736626 DOI: 10.1016/j.nmd.2021.08.007] [Reference Citation Analysis]
4 Suspitsin EN, Raupov RK, Kuchinskaya EM, Kostik MM. Analysis of interferon type I signature for differential diagnosis of diseases of the immune system ( review of literature). Klin Lab Diagn 2021;66:279-84. [PMID: 34047513 DOI: 10.51620/0869-2084-2021-66-5-279-284] [Reference Citation Analysis]
5 Hou C, Durrleman C, Periou B, Barnerias C, Bodemer C, Desguerre I, Quartier P, Melki I, Rice GI, Rodero MP, Charuel J, Relaix F, Bader‐meunier B, Authier F, Gitiaux C. From Diagnosis to Prognosis: Revisiting the Meaning of Muscle ISG15 Overexpression in Juvenile Inflammatory Myopathies. Arthritis Rheumatol 2021;73:1044-52. [DOI: 10.1002/art.41625] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
6 Voyer TL, Gitiaux C, Authier FJ, Bodemer C, Melki I, Quartier P, Aeschlimann F, Isapof A, Herbeuval JP, Bondet V, Charuel JL, Frémond ML, Duffy D, Rodero MP, Bader-Meunier B. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology (Oxford) 2021:keab116. [PMID: 33576769 DOI: 10.1093/rheumatology/keab116] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
7 Cazzato S, Omenetti A, Ravaglia C, Poletti V. Lung involvement in monogenic interferonopathies. Eur Respir Rev 2020;29:200001. [PMID: 33328278 DOI: 10.1183/16000617.0001-2020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Gupta L, Chinoy H. Monitoring disease activity and damage in adult and juvenile idiopathic inflammatory myopathy. Curr Opin Rheumatol 2020;32:553-61. [PMID: 32890032 DOI: 10.1097/BOR.0000000000000749] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
9 Melki I, Frémond M. Type I Interferonopathies: from a Novel Concept to Targeted Therapeutics. Curr Rheumatol Rep 2020;22. [DOI: 10.1007/s11926-020-00909-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]